SORL1 rare variants: a major risk factor for familial early-onset Alzheimer’s disease

Article metrics

Abstract

The SORL1 protein plays a protective role against the secretion of the amyloid β peptide, a key event in the pathogeny of Alzheimer’s disease. We assessed the impact of SORL1 rare variants in early-onset Alzheimer’s disease (EOAD) in a case–control setting. We conducted a whole exome analysis among 484 French EOAD patients and 498 ethnically matched controls. After collapsing rare variants (minor allele frequency ≤1%), we detected an enrichment of disruptive and predicted damaging missense SORL1 variants in cases (odds radio (OR)=5.03, 95% confidence interval (CI)=(2.02–14.99), P=7.49.10−5). This enrichment was even stronger when restricting the analysis to the 205 cases with a positive family history (OR=8.86, 95% CI=(3.35–27.31), P=3.82.10−7). We conclude that predicted damaging rare SORL1 variants are a strong risk factor for EOAD and that the association signal is mainly driven by cases with positive family history.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1

References

  1. 1

    Rogaeva E, Meng Y, Lee JH, Gu Y, Kawarai T, Zou F et al. The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat Genet 2007; 39: 168–177.

  2. 2

    Dodson SE, Andersen OM, Karmali V, Fritz JJ, Cheng D, Peng J et al. Loss of LR11/SORLA enhances early pathology in a mouse model of amyloidosis: evidence for a proximal role in Alzheimer's disease. J Neurosci 2008; 28: 12877–12886.

  3. 3

    Andersen OM, Reiche J, Schmidt V, Gotthardt M, Spoelgen R, Behlke J et al. Neuronal sorting protein-related receptor sorLA/LR11 regulates processing of the amyloid precursor protein. Proc Natl Acad Sci USA 2005; 102: 13461–13466.

  4. 4

    Caglayan S, Takagi-Niidome S, Liao F, Carlo AS, Schmidt V, Burgert T et al. Lysosomal sorting of amyloid-beta by the SORLA receptor is impaired by a familial Alzheimer's disease mutation. Sci Transl Med 2014; 6: 223ra20.

  5. 5

    Pottier C, Hannequin D, Coutant S, Rovelet-Lecrux A, Wallon D, Rousseau S et al. High frequency of potentially pathogenic SORL1 mutations in autosomal dominant early-onset Alzheimer disease. Mol Psychiatry 2012; 17: 875–879.

  6. 6

    McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7: 263–269.

  7. 7

    Duits FH, Prins ND, Lemstra AW, Pijnenburg YA, Bouwman FH, Teunissen CE et al. Diagnostic impact of CSF biomarkers for Alzheimer's disease in a tertiary memory clinic. Alzheimers Dement 2014; 11: 523–532.

  8. 8

    Rovelet-Lecrux A, Hannequin D, Raux G, Le Meur N, Laquerriere A, Vital A et al. APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat Genet 2006; 38: 24–26.

  9. 9

    DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, Rutherford NJ et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 2011; 72: 245–256.

  10. 10

    Beck J, Pittman A, Adamson G, Campbell T, Kenny J, Houlden H et al. Validation of next-generation sequencing technologies in genetic diagnosis of dementia. Neurobiol Aging 2014; 35: 261–265.

  11. 11

    McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res 2010; 20: 1297–1303.

  12. 12

    Li H, Durbin R . Fast and accurate long-read alignment with Burrows-Wheeler transform. Bioinformatics 2010; 26: 589–595.

  13. 13

    Wang K, Li M, Hakonarson H . ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids res 2010; 38: e164.

  14. 14

    Anderson CA, Pettersson FH, Clarke GM, Cardon LR, Morris AP, Zondervan KT . Data quality control in genetic case-control association studies. Nat Protoc 2010; 5: 1564–1573.

  15. 15

    Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ . Second-generation PLINK: rising to the challenge of larger and richer datasets. Gigascience 2015; 4: 7.

  16. 16

    Wang GT, Peng B, Leal SM . Variant association tools for quality control and analysis of large-scale sequence and genotyping array data. Am J Hum Genet 2014; 94: 770–783.

  17. 17

    Lambert JC, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims R, Bellenguez C et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet 2013; 45: 1452–1458.

  18. 18

    Young JE, Boulanger-Weill J, Williams DA, Woodruff G, Buen F, Revilla AC et al. Elucidating molecular phenotypes caused by the SORL1 Alzheimer's disease genetic risk factor using human induced pluripotent stem cells. Cell Stem Cell 2015; 16: 373–385.

  19. 19

    Vardarajan BN, Zhang Y, Lee JH, Cheng R, Bohm C, Ghani M et al. Coding mutations in SORL1 and Alzheimer disease. Ann Neurol 2015; 77: 215–227.

  20. 20

    Babron MC, de Tayrac M, Rutledge DN, Zeggini E, Genin E . Rare and low frequency variant stratification in the UK population: description and impact on association tests. PLoS One 2012; 7: e46519.

  21. 21

    Do R, Stitziel NO, Won HH, Jorgensen AB, Duga S, Angelica Merlini P et al. Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction. Nature 2015; 518: 102–106.

  22. 22

    Liu L, Sabo A, Neale BM, Nagaswamy U, Stevens C, Lim E et al. Analysis of rare, exonic variation amongst subjects with autism spectrum disorders and population controls. PLoS Genet 2013; 9: e1003443.

  23. 23

    Purcell SM, Moran JL, Fromer M, Ruderfer D, Solovieff N, Roussos P et al. A polygenic burden of rare disruptive mutations in schizophrenia. Nature 2014; 506: 185–190.

Download references

Acknowledgements

This study was funded by grants from the Clinical Research Hospital Program from the French Ministry of Health (GMAJ, PHRC 2008/067), the CNR-MAJ, the JPND PERADES and France Génomique. This work was supported by Labex GENMED ANR-10-LABX-0013, the National Foundation for Alzheimer’s disease and related disorders, the Institut Pasteur de Lille, the Centre National de Génotypage, Inserm, FRC (fondation pour la recherche sur le cerveau) and Rotary. This work has been supported by the LABEX (laboratory of excellence program investment for the future) DISTALZ grant (Development of Innovative Strategies for a Transdisciplinary approach to ALZheimer’s disease). The funding sources had no specific roles.

Author information

Correspondence to D Campion.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Didier Hannequin, Dominique Campion, David Wallon, Olivier Martinaud, Gaël Nicolas (Centre Hospitalo-Universitaire (CHU), Rouen); Olivier Godefroy (CHU Amiens); Frédérique Etcharry-Bouyx, Valérie Chauviré (CHU Angers); Ludivine Chamard, Eric Berger, Eloi Magnin (CHU Besancon); Jean-Francois Dartigues, Sophie Auriacombe (CHU Bordeaux); Vincent de la Sayette, Fausto Viader (CHU Caen); Dominique Castan (CH Castres), Elsa Dionet (CHU Clermont-Ferrand); Francois Sellal (CH Colmar); Olivier Rouaud, Christel Thauvin (CHU Dijon); Olivier Moreaud, Mathilde Sauvée (CHU Grenoble); Adeline Rollin-Sillaire, Stéphanie Bombois, Marie-Anne Mackowiak, Vincent Deramecourt, Florence Pasquier (CHU Lille); Maïté Formaglio, Hélène Mollion, Isabelle Roullet-Solignac, Alain Vighetto, Bernard Croisile (CHU Lyon); Mira Didic, Olivier Félician, Lejla Koric, Mathieu Ceccaldi (CHU Marseille); Audrey Gabelle, Cecilia Marelli, Jacques Touchon, Pierre Labauge (CHU Montpellier); Thérèse Jonveaux (CHU Nancy); Martine Vercelletto, Claire Boutoleau-Bretonnière (CHU Nantes); Giovanni Castelnovo (CHU Nimes); David Renaud, Philippe Robert (CHU de Nice); Claire Paquet, Julien Dumurgier, Jacques Hugon (CHU Lariboisière, Paris); Agnès Michon, Isabelle Le Ber, Bruno Dubois, Charles Duyckaerts (CHU La Salpêtrière, Paris); Foucauld De Boisgueheneuc (CHU Poitiers); Serge Belliard (CHU Rennes); Serge Bakchine (CHU de Reims); Marie-Odile Barrellon, Bernard Laurent (CHU Saint-Etienne); Frédéric Blanc, Christine Tranchant (CHU Strasbourg); Jérémie Pariente, Michèle Puel (CHU Toulouse); Caroline Hommet, Karl Mondon (CHU Tours).

Supplementary Information accompanies the paper on the Molecular Psychiatry website

Supplementary information

Supplementary Figure 1 (JPG 72 kb)

Supplementary Information (DOCX 12 kb)

PowerPoint slides

PowerPoint slide for Fig. 1

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Further reading